Literature DB >> 32399411

Elevated VEGF-A & PLGF concentration in aqueous humor of patients with uveal melanoma following Iodine-125 plaque radiotherapy.

Meng-Xi Chen1, Yue-Ming Liu1, Yang Li1, Xuan Yang1, Wen-Bin Wei1.   

Abstract

AIM: To measure the concentration of vascular endothelial growth factor-A (VEGF-A), and placental growth factor (PLGF) in aqueous humor of uveal melanoma patients before and after Iodine-125 plaque therapy (IPT), determine the postoperative fluctuation and evaluate associated factors in vivo.
METHODS: Participants were 18 Chinese patients with uveal melanoma who were elected to IPT. Undiluted aqueous humor samples were collected at Iodine plaque implant and removal time, then stored immediately at -80°C until assayed. The concentration of VEGF-A, PLGF and other 7 cytokines comprising interleukin-2 (IL-2), IL-8, IL-10, interferon (IFN)-γ, programmed death (PD)-1, transforming growth factor (TGF)-β1 and insulin-like growth factor (IGF)-1 in aqueous humor was measured using Raybiotech immunoassay kit, a high throughput strategy. The VEGF-A and PLGF levels were compared across preoperation and postoperation subgroups, as well as those of other 7 interleukins. Correlation and grouped analyses were conducted to determine the independent effects of clinical parameters and other cytokines on VEGF-A and PLGF concentration or fluctuation. This study set a self-control design.
RESULTS: VEGF-A (P=0.038) and PLGF (P=0.026) were the only two increased cytokines after IPT. Preoperative and postoperative level of VEGF-A and PLGF (r=0.575, P=0.013; r=0.987, P<0.001) correlated with each other significantly. Level of VEGF-A (r=0.626, P=0.005; r=0.588, P=0.01) and PLGF (r=0.616, P=0.007; r=0.588, P=0.01) had positive correlation with tumor thickness consistently. Elevated VEGF-A or PLGF level were strong predictive factors of each other (P=0.007, OR=60.0). The elevated VEGF-A group showed a higher postoperative level of IFN-γ (P=0.005), IL-2 (P<0.001) and IL-10 (P=0.004) in aqueous humor. When the elevated PLGF group got similar results that a higher postoperative level of IFN-γ (P=0.007), IL-2 (P<0.001) and IL-10 (P=0.013) in aqueous humor.
CONCLUSION: This study reveals that VEGF-A and PLGF in aqueous humor significantly increased with tumor thickness and radiation process in uveal melanoma patients. VEGF-A and PLGF may be crucial in uveal melanoma genesis and radiotherapy reactions. Immune mediators comprised IFN-γ, IL-2 and IL-10 could play roles in the link between inflammation and angiogenesis in uveal melanoma when exposed to radiotherapy. International Journal of Ophthalmology Press.

Entities:  

Keywords:  placental growth factor; radioplaque therapy; uveal melanoma; vascular endothelial growth factor-A

Year:  2020        PMID: 32399411      PMCID: PMC7137709          DOI: 10.18240/ijo.2020.04.11

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  38 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Uveal melanoma: the inflammatory microenvironment.

Authors:  Inge H G Bronkhorst; Martine J Jager
Journal:  J Innate Immun       Date:  2012-02-01       Impact factor: 7.349

Review 3.  The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer.

Authors:  Roy M Bremnes; Khalid Al-Shibli; Tom Donnem; Rafael Sirera; Samer Al-Saad; Sigve Andersen; Helge Stenvold; Carlos Camps; Lill-Tove Busund
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

Review 4.  Melanoma of the eye: revealing hidden secrets, one at a time.

Authors:  Carol L Shields; Jane Grant Kels; Jerry A Shields
Journal:  Clin Dermatol       Date:  2015-01-14       Impact factor: 3.541

Review 5.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

6.  Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.

Authors:  Jeffrey L Wong; Robbie B Mailliard; Stergios J Moschos; Howard Edington; Michael T Lotze; John M Kirkwood; Pawel Kalinski
Journal:  J Immunother       Date:  2011-04       Impact factor: 4.456

7.  Population-based incidence of uveal melanoma in various races and ethnic groups.

Authors:  Dan-Ning Hu; Guo-Pei Yu; Steven A McCormick; Susan Schneider; Paul T Finger
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

8.  Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy.

Authors:  Devron H Char; Stewart Kroll; Theodore L Phillips; Jeanne M Quivey
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

9.  The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma.

Authors: 
Journal:  Brachytherapy       Date:  2013-12-24       Impact factor: 2.362

Review 10.  The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.

Authors:  Holly E Barker; James T E Paget; Aadil A Khan; Kevin J Harrington
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

View more
  3 in total

Review 1.  Proteomics in uveal melanoma.

Authors:  Michael J Heiferman; Vinit B Mahajan; Prithvi Mruthyunjaya
Journal:  Curr Opin Ophthalmol       Date:  2022-01-31       Impact factor: 4.299

2.  Contribution of the STAT Family of Transcription Factors to the Expression of the Serotonin 2B (HTR2B) Receptor in Human Uveal Melanoma.

Authors:  Manel Benhassine; Gaëtan Le-Bel; Sylvain L Guérin
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

3.  Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.

Authors:  Prisca Bustamante; Thupten Tsering; Jacqueline Coblentz; Christina Mastromonaco; Mohamed Abdouh; Cristina Fonseca; Rita P Proença; Nadya Blanchard; Claude Laure Dugé; Rafaella Atherino Schmidt Andujar; Emma Youhnovska; Miguel N Burnier; Sonia A Callejo; Julia V Burnier
Journal:  J Exp Clin Cancer Res       Date:  2021-06-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.